MGNX: MacroGenics, Inc. Stock

by  •  • Comments Off on MGNX: MacroGenics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 79.49
Enterprise Value ($M) -108.39
Book Value ($M) 116.06
Book Value / Share 1.84
Price / Book 0.64
NCAV ($M) 71.89
NCAV / Share 1.14
Price / NCAV 1.11

Profitability (mra)
Return on Invested Capital (ROIC) -0.44
Return on Assets (ROA) -0.27
Return on Equity (ROE) -0.63

Liquidity (mrq)
Quick Ratio 3.86
Current Ratio 3.92

Balance Sheet (mrq) ($M)
Current Assets 217.49
Assets 261.65
Liabilities 145.60
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 149.96
Operating Income -110.58
Net Income -66.97
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -68.37
Cash from Investing 149.30
Cash from Financing 0.96

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
2 days ago 13G/A Millennium Management Llc 2.70 -46.28
02-14 13G/A Bb Biotech Ag 15.80 0.00
02-14 13G/A Armistice Capital, Llc 9.99 0.29
02-14 13G/A Ra Capital Management, L.p. 0.00 -100.00
02-11 13G Wasatch Advisors Inc 5.60
11-20 13G Frazier Life Sciences Public Fund, L.P. 5.10
11-08 13G/A BlackRock, Inc. 8.60 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-20 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSU
2024-08-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT T
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 190,292 678,374 28.05
2025-04-16 195,795 641,981 30.50
2025-04-15 79,765 276,564 28.84
2025-04-14 230,278 655,489 35.13

(click for more detail)

Similar Companies
LYEL – Lyell Immunopharma, Inc. MCRB – Seres Therapeutics, Inc.
MDGL – Madrigal Pharmaceuticals, Inc. MGTX – MeiraGTx Holdings plc
MIST – Milestone Pharmaceuticals Inc.


Financial data and stock pages provided by
Fintel.io